NCT04158869 is a clinical trial in Major Depressive Disorder, sponsored by Swiss Federal Institute of Technology.

Who is sponsoring NCT04158869?

NCT04158869 is sponsored by Swiss Federal Institute of Technology.

What condition does NCT04158869 study?

NCT04158869 studies Major Depressive Disorder, Depression, Child Mental Disorder.

Is NCT04158869 still recruiting?

NCT04158869 is currently completed. Last updated 11 January 2022.

Last reviewed 2022-01-11 · How we verify

NCT04158869

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Investigation of the Relationship Between Omega-3 Fatty Acid Nutrition and Mental Health in Children and Adolescents

Completed Last updated 11 January 2022

What this trial tests

trial in Major Depressive Disorder in 190 participants. Completed in 22 December 2020.

Timeline

16 September 2019

Primary endpoint
22 December 2020

22 December 2020

Quick facts

Lead sponsor	Swiss Federal Institute of Technology
Status	Completed
Study type	OBSERVATIONAL
Enrollment	190
Start date	16 September 2019
Primary completion	22 December 2020
Estimated completion	22 December 2020
Sites	1 location across Switzerland

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →
Depression — all drugs for Depression →
Child Mental Disorder — all drugs for Child Mental Disorder →

Sponsor

Swiss Federal Institute of Technology

Who can join

Adults 8 to 17, any sex, with Major Depressive Disorder or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational case-control add-on study to an investigator-initiated clinical trial (IICT) (ClinicalTrials.gov Identifier: NCT03167307): Omega-3 fatty acids as firstline treatment in pediatric depression. A 36-week multi-centre, double-blind, placebo-controlled randomized superiority study. This project will recruit a healthy control group matched for age and sex to a sub-group of patients with diagnosed pediatric major depressive disorder (pMDD) enrolled in the IICT. The aim is to investigate the relationship of n-3 FA intake and status with mental health in children and adolescents with and without diagnosed pMDD, and explore potential biochemical mechanisms underlying this relationship by measuring biomarkers related to n-3 FA metabolism, mental health and cognitive function.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Iron status in Swiss adolescents with paediatric major depressive disorder and healthy controls: a matched case-control study.
Osuna E, Baumgartner J, Wunderlin O, Emery S, et al · · 2024 · cited 8× · PMID 38265750 · DOI 10.1007/s00394-023-03313-7
Major depressive disorder in children and adolescents is associated with reduced hair cortisol and anandamide (AEA): cross-sectional and longitudinal evidence from a large randomized clinical trial.
Walther A, Eggenberger L, Debelak R, Kirschbaum C, et al · · 2025 · cited 4× · PMID 40413177 · DOI 10.1038/s41398-025-03401-8
Investigating thyroid function and iodine status in adolescents with and without paediatric major depressive disorder.
Osuna E, Baumgartner J, Walther A, Emery S, et al · · 2024 · cited 1× · PMID 39387198 · DOI 10.1017/s0007114524001910
Altered Plasma Endocannabinoids and Oxylipins in Adolescents with Major Depressive Disorders: A Case-Control Study.
Chakravarty A, Sreetharan A, Osuna E, Herter-Aeberli I, et al · · 2026 · PMID 41599894 · DOI 10.3390/nu18020280

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Swiss Federal Institute of Technology trials

Trials by the same sponsor.

NCT07182734 — Feasibility of Unsupervised Therapy After Neurological or Orthopaedical Injury in the Home Setting With a Hand Rehabilit · NA · not yet recruiting
NCT06725784 — Feasibility and Cost of Robot-assisted Upper Limb Rehabilitation with Different Levels of Supervision · NA · recruiting
NCT06851130 — Assessing the Immediate Increase in Serum Ferritin After Oral Iron Doses: an Experimental Study in Iron-deficient Women · NA · recruiting
NCT06149975 — Feasibility of a Motor-cognitive Training Program in Patients With Traumatic Brain Injury · NA · completed
NCT06116669 — Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04158869 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Federal Institute of Technology
Last refreshed: 11 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04158869.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing